Showing 2421-2430 of 5771 results for "".
- Schwind Announces 825,000 Treatments Performed With No-Touch Eye Laser Treatmenthttps://modernod.com/news/schwind-announces-825000-treatments-performed-with-no-touch-eye-laser-treatment/2479865/Schwind announced that more than 825,000 no-touch eye laser treatment treatments have been performed so far. SmartSurfACE, the proprietary TransPRK procedure from Schwind, continues to grow rapidly. Using Trans
- Iridex Announces MicroPulse Treatment Symposium at ESCRShttps://modernod.com/news/iridex-announces-micropulse-treatment-symposium-at-escrs/2479868/Iridex announced they will be hosting a symposium at the Annual Meeting of the European Society for Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria on September 22, 2018. “MicroPulse Technology: Latest Trends in Laser Treatment Choices for Glaucoma and
- Excel-Lens Announces CE Mark Approval for CAPSULaser Selective Laser Capsulotomy (SLC) Devicehttps://modernod.com/news/excel-lens-announces-ce-mark-approval-for-capsulaser-selective-laser-capsulotomy-slc-device/2479872/Excel-Lens announced the CE mark approval of CAPSULaser, a selective laser that creates a capsulotomy during cataract surgery in just over a second. The laser energy is delivered in a continuous manner rather than a pulsed beam which can create tissue bridges. In clinical studies, CAPSULas
- Allergan Announces New Partnership With the International Diabetes Federationhttps://modernod.com/news/allergan-announces-new-partnership-with-the-international-diabetes-federation/2479873/Allergan has announced a collaborative partnership with the International Diabetes Federation (IDF) with the aim of developing a global approach to screen, diagnose, and manage diabetic macular edema (DME). Diabetic eye health is a key concern for IDF and Allergan. The partnership will bri
- Zeiss Announces 1.5 Million SMILE Procedures Performedhttps://modernod.com/news/zeiss-announces-1-5-million-smile-procedures-performed/2479875/Zeiss announced two milestones in refractive technology: the completion of 1.5 million treatments with SMILE and the production of its 1,000th VisuMax femtosecond laser.
- Katena Products Announces Launch of the New Katena.comhttps://modernod.com/news/katena-products-announces-launch-of-the-new-katena-com/2479878/Katena Products has announced the launch of the new katena.com, an interactive and engaging ecommerce and education portal. The new site enables existing and prospective customers to review the complete assortment of Katena products and immediately order online. The new site integrates all
- Staar Surgical Announces FDA Approval of the Visian Toric ICL for the Correction of Myopia with Astigmatismhttps://modernod.com/news/staar-surgical-announces-fda-approval-of-the-visian-toric-icl-for-the-correction-of-myopia-with-astigmatism/2479890/Staar Surgical announced that the FDA has granted approval of the PMA supplement for the Visian Toric ICL for the correction of myopia with astigmatism. This approval represents an expansion of the Implantable Collamer Lens (ICL) product line for the correction of refractive error in patie
- Oculus Announces Release of Smartfield Smart Compact Perimeterhttps://modernod.com/news/oculus-announces-release-of-smartfield-smart-compact-perimeter/2479897/Oculus has announced the release of its Smartfield perimeter, expanding its portfolio of compact visual field testing devices. The new Smartfield has been optimized specifically for examinations for functional impairment of the central visual field, but is also suited for peripheral measurements.
- Apellis Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophyhttps://modernod.com/news/apellis-announces-first-patient-dosed-in-its-phase-3-clinical-program-for-apl-2-in-patients-with-geographic-atrophy/2479898/Apellis Pharmaceuticals announced that it has commenced its phase 3 clinical program for APL-2 in patients with geographic atrophy (GA), consisting of two phase 3 trials (DERBY & OAKS.) The first patient has been dosed in the OAKS trial and the first patient has been enrolled in the
- Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker “OXUR” and Launch of New Websitehttps://modernod.com/news/oxurion-nv-announces-new-nyse-euronext-brussels-stock-ticker-oxur-and-launch-of-new-website/2479904/Oxurion NV announced the start of today’s trading under “OXUR” on NYSE Euronext Brussels. Effective today, the launch of a new ticker and website (